Previous Close | 83.87 |
Open | 84.13 |
Bid | 85.99 x 800 |
Ask | 86.00 x 1000 |
Day's Range | 83.66 - 84.67 |
52 Week Range | 76.02 - 100.38 |
Volume | |
Avg. Volume | 1,373,876 |
Market Cap | 15.813B |
Beta (5Y Monthly) | 0.31 |
PE Ratio (TTM) | 96.33 |
EPS (TTM) | 0.87 |
Earnings Date | Apr 24, 2024 - Apr 29, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 109.48 |
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive early results from an investigator-sponsored Phase 2 study of VOXZOGO® (vosoritide) in children with hypochondroplasia, will be presented at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada, March 12-16, 2024. Researchers will also present data from Phase 2 and Phase 3 studies of the medicine in children with achondroplasia, including results that demonstrate V
The company is a leader in the global achondroplasia treatment market
Henry Fuchs, President, Worldwide Research & Development at Biomarin Pharmaceutical Inc (NASDAQ:BMRN), sold 35,341 shares of the company on March 5, 2024, according to a recent SEC filing.